Singapore’s Health Sciences Authority opened consultation on proposed medicine-change checklists on 16 November 2026, with comments due by 31 December. The chemical and biological therapeutic-product drafts give university spinouts and translational medicine teams an opportunity to examine evidence requirements for changes after product registration. A separate survey covers readiness for electronic product information.
HSA releases two proposed minor-variation checklists
The HSA regulatory update invites industry feedback on revised Minor Variation, or MIV, checklists. The agency says its aim is clearer requirements and easier preparation of applications for changes to registered therapeutic products. It provides separate chemical and biological drafts, a feedback spreadsheet and an online submission form.
The scope is the registered product’s lifecycle. Researchers planning a study should distinguish this exercise from Singapore’s clinical-trial authorization pathways. The consultation offers a chance to comment on proposed postapproval documentation, rather than granting permission to conduct a clinical trial.
What the draft checklists would ask registrants to document
The chemical-products draft, Appendix 13, uses three reporting categories: MIV-1, MIV-2 Notification and MIV-2 Do-and-Tell. Its structure covers administrative changes, drug-substance quality, drug-product quality, regulatory tools and product labelling. Each proposed classification depends on the applicable conditions; the draft distinguishes conditions shared across a checklist group from those attached to a particular subcategory.
Appendix 13 also calls for applications to identify primary and consequential changes explicitly. Its proposed summary table records the affected dossier section, approved and proposed information, the reason for the change, and relevant overseas regulatory status. For chemical changes supported by a Drug Master File, the draft says HSA should receive the electronic file before the corresponding variation application.
The biological-products draft, Appendix 14, adds a particularly relevant point for translational manufacturing: where changes to sites, processes, scale, cell or seed banks, or other quality elements may affect critical quality attributes, the evidence package should demonstrate comparability of material before and after the change, as applicable.
Appendix 14 also says a proposed host-cell-line change should be discussed with HSA before submission and may require a new application. That qualification matters when reviewing a project under a heading labelled minor variation. The biological draft describes checklist evidence as minimum requirements and allows HSA to request more information.
The November opening follows September’s advance notice
HSA’s 30 September 2026 registration update had already announced that it was reviewing the MIV checklist and expected industry consultation from mid-November to mid-December. The new development on 16 November is the publication of the drafts and the opening of feedback, with a stated closing date of 31 December.
The September notice also dealt with Appendix 17 guidance on packaging configurations and corresponding updates to other registration appendices, effective from 30 September. Those implemented packaging changes and the newly opened MIV consultation are separate regulatory developments. Their different status is relevant when a team decides which document governs a current submission and which document invites comment.
HSA and sector reporting emphasize the proposal’s status
HSA frames the consultation as an effort to make the checklists practical and clear. Asia Pharma Today’s 17 November report likewise describes a consultation on drafts and distinguishes it from an in-force checklist or product approval. Its coverage treats the electronic-information survey as a separate exercise. That distinction supports reviewing the proposals while keeping current filing decisions anchored to applicable requirements.
The FHIR survey concerns readiness for structured information
The accompanying survey asks about readiness for electronic product information in Fast Healthcare Interoperability Resources format, anticipated implementation challenges and potential benefits for healthcare professionals and patients. HL7, which publishes FHIR, describes it as a healthcare data-exchange standard. Its documentation includes resource definitions, terminology and mechanisms for recording provenance and audit events.
For research informatics teams, this supplies technical context for the survey: structured exchange involves how information is represented and connected across systems. CASRAI’s FHIR background guide explains that wider architecture. The HSA exercise is a readiness survey; it does not announce a requirement to buy software or implement a particular FHIR release.
Implications for university spinouts and research teams
For university ventures working with registered therapeutic products, the practical opportunity is to test the drafts against planned changes and identify where the proposed evidence expectations need clarification. As an editorial assessment, a useful review would connect the proposed checklist item to the evidence owner, the affected dossier sections and any linked labelling updates. This applies the drafts’ logic to pharmaceutical change control; it creates no additional HSA obligation.
The division of work matters. A biological-development team can assess the comparability question, quality staff can trace supporting records, and regulatory colleagues can review classification and consequential changes. Research offices supporting technology transfer can coordinate that review with the venture’s registrant. These are planning implications of the proposals, rather than instructions to start new studies or change an approved product immediately.
Feedback and survey responses are due on December 31
HSA asks participants to submit the completed consultation spreadsheet through its linked consultation form by 31 December 2026. It welcomes comments on categories, conditions and supporting data. The separate ePI survey has the same deadline. Teams preparing a response can therefore direct checklist questions and digital-information readiness feedback through the respective routes linked in the agency’s notice.
Sources
- Health Sciences Authority: Regulatory Updates (16 Nov 2026), 16 November 2026; checked 2026-11-17.
- Health Sciences Authority: Appendix 13, Guideline on Minor Variation Applications for Chemical Therapeutic Products — Draft for Consultation, released with the 16 November 2026 notice; checked 2026-11-17.
- Health Sciences Authority: Appendix 14, Guideline on Minor Variation Applications for Biological Therapeutic Products — Draft for Consultation, released with the 16 November 2026 notice; checked 2026-11-17.
- Health Sciences Authority: Regulatory Updates for Therapeutic Product Registration, 30 September 2026; checked 2026-11-17.
- Asia Pharma Today: Singapore asks industry to review draft minor-variation checklists, 17 November 2026; checked 2026-11-17.
- HL7: FHIR specification index, technical background; checked 2026-11-17.







